methylphenidate ER
Selected indexed studies
- Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. (Lancet Psychiatry, 2023) [PMID:36958362]
- Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. (Expert Rev Clin Pharmacol, 2023) [PMID:37587841]
- Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. (Expert Opin Pharmacother, 2024) [PMID:38771653]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. (2024) pubmed
- Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. (2023) pubmed
- Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. (2023) pubmed
- QuilliChew ER--extended-release chewable methylphenidate tablets. (2016) pubmed
- Safety and effectiveness of methylphenidate ER multi-unit pellet system in ADHD patients: An open label study. (2024) pubmed
- Viloxazine ER (Qelbree) for ADHD. (2021) pubmed
- Pharmacokinetics and Bioequivalence of a Novel Extended-Release Formulation of Methylphenidate Hydrochloride for Attention-Deficit/Hyperactivity Disorder. (2025) pubmed
- Methylphenidate-induced spontaneous ejaculation. (2015) pubmed
- Pharmacokinetics of Long-Acting Methylphenidate: Formulation Differences, Bioequivalence, Interchangeability. (2024) pubmed
- New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability. (2017) pubmed